Outsmarting HIV

Small molecules that mimic the T-cell surface receptor CD4 could expose the virus to antibody-based immune responses.

Written byJef Akst
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

HIV-infected T cellFLICKR, NIAIDThe T-cell surface receptor CD4 is necessary for HIV to enter host cells. Once the virus is inside, however, the CD4 receptor makes HIV vulnerable, by altering the conformation of the envelope glycoprotein in a way that exposes it to effective antibodies. To evade this immune response, HIV-1, the most common serotype of the virus, downregulates CD4. To make the virus susceptible to antibody-based destruction once again, researchers decided to present infected cells with small molecule mimics of CD4, forcing HIV’s envelope glycoprotein back into a vulnerable state. Their results were published today (May 4) in PNAS.

“The virus has to get rid of the CD4 proteins to protect itself,” study coauthor Jonathan Richard, a postdoctoral researcher at the University of Montreal’s CHUM Research Centre, said in a press release. “Adding the small molecule forces the viral envelop to open, like a flower. The antibodies that are naturally present after the infection can then target the infected cells so they are killed by the immune system.”

The results could be key to an effective treatment, added study coauthor Andrés Finzi, also of the CHUM Research Centre. “We found that people infected with the HIV-1 virus have naturally occurring antibodies that have the potential to kill the infected cells. We just have to give them a little push by adding a tiny molecule ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies